Literature DB >> 23131591

An integrated approach to the ligand binding specificity of Neisseria meningitidis M1 alanine aminopeptidase by fluorogenic substrate profiling, inhibitory studies and molecular modeling.

Ewelina Węglarz-Tomczak1, Marcin Poręba, Anna Byzia, Łukasz Berlicki, Bogusław Nocek, Rory Mulligan, Andrzej Joachimiak, Marcin Drąg, Artur Mucha.   

Abstract

Neisseria meningitides is a gram-negative diplococcus bacterium and is the main causative agent of meningitis and other meningococcal diseases. Alanine aminopeptidase from N. meningitides (NmAPN) belongs to the family of metallo-exopeptidase enzymes, which catalyze the removal of amino acids from the N-terminus of peptides and proteins, and are found among all the kingdoms of life. NmAPN is suggested to be mostly responsible for proteolysis and nutrition delivery, similar to the orthologs from other bacteria. To explore the possibility of NmAPN being a potential drug target for inhibition and development of novel therapeutic agents, the specificity of the S1 and S1' binding sites was explored using an integrated approach. Initially, an extensive library consisting of almost 100 fluorogenic substrates derived from both natural and unnatural amino acids, were used to obtain a detailed substrate fingerprint of the S1 pocket of NmAPN. A broad substrate tolerance of NmAPN was revealed, with bulky basic and hydrophobic ligands being the most favored substrates. Additionally, the potency of a set of organophosphorus inhibitors of neutral aminopeptidases, amino acid and dipeptide analogs was determined. Inhibition constants in the nanomolar range, determined for phosphinic dipeptides, proves the positive increase in inhibition impact of the P1' ligand elongation. The results were further verified via molecular modeling and docking of canonical aminopeptidase phosphinic dipeptide inhibitors in the NmAPN active site. These studies present comprehensive characterization of interactions responsible for specific ligand binding. This knowledge provides invaluable insight into understanding of the enzyme and development of novel NmAPN inhibitors.
Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23131591      PMCID: PMC3557594          DOI: 10.1016/j.biochi.2012.10.018

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  33 in total

1.  Crystal structure of aminopeptidase N from human pathogen Neisseria meningitidis.

Authors:  B Nocek; R Mulligan; M Bargassa; F Collart; A Joachimiak
Journal:  Proteins       Date:  2008-01-01

Review 2.  Acute bacterial meningitis.

Authors:  Sharon E Mace
Journal:  Emerg Med Clin North Am       Date:  2008-05       Impact factor: 2.264

3.  Crystal structure of aminopeptidase N (proteobacteria alanyl aminopeptidase) from Escherichia coli and conformational change of methionine 260 involved in substrate recognition.

Authors:  Kiyoshi Ito; Yoshitaka Nakajima; Yuko Onohara; Masahide Takeo; Kanako Nakashima; Futoshi Matsubara; Takashi Ito; Tadashi Yoshimoto
Journal:  J Biol Chem       Date:  2006-08-02       Impact factor: 5.157

4.  alpha-Aminoalkylphosphonates as a tool in experimental optimisation of P1 side chain shape of potential inhibitors in S1 pocket of leucine- and neutral aminopeptidases.

Authors:  Marcin Drag; Jolanta Grembecka; Małgorzata Pawełczak; Paweł Kafarski
Journal:  Eur J Med Chem       Date:  2005-04-20       Impact factor: 6.514

5.  EFNS guideline on the management of community-acquired bacterial meningitis: report of an EFNS Task Force on acute bacterial meningitis in older children and adults.

Authors:  A Chaudhuri; P Martinez-Martin; P M Martin; P G E Kennedy; R Andrew Seaton; P Portegies; M Bojar; I Steiner
Journal:  Eur J Neurol       Date:  2008-07       Impact factor: 6.089

6.  Identification of phosphinate dipeptide analog inhibitors directed against the Plasmodium falciparum M17 leucine aminopeptidase as lead antimalarial compounds.

Authors:  Tina S Skinner-Adams; Jonathan Lowther; Franka Teuscher; Colin M Stack; Jolanta Grembecka; Artur Mucha; Pawel Kafarski; Katharine R Trenholme; John P Dalton; Donald L Gardiner
Journal:  J Med Chem       Date:  2007-10-26       Impact factor: 7.446

7.  Structural basis for the unusual specificity of Escherichia coli aminopeptidase N.

Authors:  Anthony Addlagatta; Leslie Gay; Brian W Matthews
Journal:  Biochemistry       Date:  2008-04-17       Impact factor: 3.162

Review 8.  The structure and main functions of aminopeptidase N.

Authors:  Yepeng Luan; Wenfang Xu
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

Review 9.  Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects.

Authors:  Brigitte Bauvois; Daniel Dauzonne
Journal:  Med Res Rev       Date:  2006-01       Impact factor: 12.944

Review 10.  The moonlighting enzyme CD13: old and new functions to target.

Authors:  Paola Mina-Osorio
Journal:  Trends Mol Med       Date:  2008-07-05       Impact factor: 11.951

View more
  10 in total

1.  A structural insight into the P1S1 binding mode of diaminoethylphosphonic and phosphinic acids, selective inhibitors of alanine aminopeptidases.

Authors:  Ewelina Węglarz-Tomczak; Łukasz Berlicki; Małgorzata Pawełczak; Bogusław Nocek; Andrzej Joachimiak; Artur Mucha
Journal:  Eur J Med Chem       Date:  2016-04-09       Impact factor: 6.514

2.  P1' Residue-Oriented Virtual Screening for Potent and Selective Phosphinic (Dehydro) Dipeptide Inhibitors of Metallo-Aminopeptidases.

Authors:  Michał Talma; Artur Mucha
Journal:  Biomolecules       Date:  2020-04-24

Review 3.  M1 aminopeptidases as drug targets: broad applications or therapeutic niche?

Authors:  Nyssa Drinkwater; Jisook Lee; Wei Yang; Tess R Malcolm; Sheena McGowan
Journal:  FEBS J       Date:  2017-02-03       Impact factor: 5.542

4.  Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2.

Authors:  Ewelina Weglarz-Tomczak; Jakub M Tomczak; Michał Talma; Małgorzata Burda-Grabowska; Mirosław Giurg; Stanley Brul
Journal:  Sci Rep       Date:  2021-02-11       Impact factor: 4.379

Review 5.  Patient-derived tumor models are attractive tools to repurpose drugs for ovarian cancer treatment: pre-clinical updates.

Authors:  Magdalena Cybula; Magdalena Bieniasz
Journal:  Oncotarget       Date:  2022-03-24

6.  Synthesis of fluorescent (benzyloxycarbonylamino)(aryl)methylphosphonates.

Authors:  Michał Górny Vel Górniak; Anna Czernicka; Piotr Młynarz; Waldemar Balcerzak; Paweł Kafarski
Journal:  Beilstein J Org Chem       Date:  2014-03-28       Impact factor: 2.883

7.  A remarkable activity of human leukotriene A4 hydrolase (LTA4H) toward unnatural amino acids.

Authors:  Anna Byzia; Jesper Z Haeggström; Guy S Salvesen; Marcin Drag
Journal:  Amino Acids       Date:  2014-02-27       Impact factor: 3.520

8.  Structure-guided, single-point modifications in the phosphinic dipeptide structure yield highly potent and selective inhibitors of neutral aminopeptidases.

Authors:  Stamatia Vassiliou; Ewelina Węglarz-Tomczak; Łukasz Berlicki; Małgorzata Pawełczak; Bogusław Nocek; Rory Mulligan; Andrzej Joachimiak; Artur Mucha
Journal:  J Med Chem       Date:  2014-09-22       Impact factor: 7.446

Review 9.  Synthesis and modifications of phosphinic dipeptide analogues.

Authors:  Artur Mucha
Journal:  Molecules       Date:  2012-11-15       Impact factor: 4.411

10.  X-ray crystal structure and specificity of the Toxoplasma gondii ME49 TgAPN2.

Authors:  Emilia M Marijanovic; Karolina Weronika Swiderska; James Andersen; Jasmin C Aschenbrenner; Chaille T Webb; Marcin Drag; Nyssa Drinkwater; Sheena McGowan
Journal:  Biochem J       Date:  2020-10-16       Impact factor: 3.857

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.